AbbVie 8-K

Summary

Q3 2026 results, with FY2026 adjusted diluted EPS guidance raised. Revenue increased 10.3% to $17.4B, led by growth in immunology and neuroscience; AbbVie also completed its Apogee Therapeutics acquisition, adding immunology pipeline assets. The board raised the quarterly dividend 5.2%, from $1.73 to $1.82 per share, beginning with the payment on 2/16/2027 to shareholders of record on 1/15/2027.

Key Figures

• Immunology revenue was $9.17B, +16.3% reported; Skyrizi was $5.78B (+22.7%) and Rinvoq $2.71B (+23.9%), while Humira declined 31.2% to $683M. Neuroscience revenue grew 19.4% to $3.39B, including Qulipta at $398M (+38.2%) and Ubrelvy at $449M (+26.9%). Oncology was nearly flat at $1.70B (+0.8%), with Imbruvica down 26.1%; aesthetics declined 1.4% to $1.18B, including Juvederm down 11.9%.
• The completed Apogee acquisition adds zumilokibart, a late-stage, half-life-extended antibody targeting IL-13 for atopic dermatitis, and APG273, a potential long-acting IL-13/TSLP combination for asthma. AbbVie also reported FDA approval of subcutaneous Skyrizi induction for Crohn’s disease and FDA approval of Juvmo for Parkinson’s disease.
• Phase 3 lutikizumab results in hidradenitis suppurativa met the primary endpoint; AbbVie expects additional 36-week extension data next year and plans to use the results to support regulatory submissions in the second half of 2027. Q3 GAAP and non-GAAP diluted EPS each included a $0.11 unfavorable impact from acquired IPR&D and milestone expense.

Against earlier guidance (derived from earlier filings)

Guidance

The guidance includes a $0.69 per-share unfavorable impact from acquired IPR&D and milestone expense incurred through Q3; it excludes any such expense incurred after Q3, which AbbVie says cannot be reliably forecast.

Guidance changes, derived from earlier filings

Metric	Period	Earlier guidance	Guidance now	Change
Adjusted diluted EPS, non-GAAP	FY2026	$13.76-$13.96	$13.95-$13.99	raised

Investor Takeaways

• Watch Skyrizi and Rinvoq revenue growth in coming quarters: continued growth from their Q3 levels would sustain immunology’s momentum, while a slowdown would weaken that evidence.
• Watch for the lutikizumab extension results next year and the planned second-half 2027 regulatory submissions; those developments will test whether the Phase 3 hidradenitis suppurativa results support the next development step.